Skip to main content

Table 3 Categorization of irAEs

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

irAEs

No. (%)

Median days to onset

Grade of irAEs, n, 1/2/3/4

Diarrhea/colitis

5 (7.7)

60.0

2/2/1/0

Hyperglycemia

2 (3.1)

398.5

0/0/2/0

Pruritus

2 (3.1)

50.0

2/0/0/0

Rash

2 (3.1)

12.0

1/1/0/0

Type 1 DM

2 (3.1)

398.5

0/2/0/0

Adrenal insufficiency

1 (1.5)

143.0

0/0/1/0

ALT increased

1 (1.5)

28.0

0/1/0/0

AST increased

1 (1.5)

28.0

0/0/1/0

Appetite loss

1 (1.5)

158.0

1/0/0/0

Hypothyroidism

1 (1.5)

167.0

1/0/0/0

Dry skin

1 (1.5)

29.0

1/0/0/0

Edema limbs

1 (1.5)

28.0

1/0/0/0

Myalgia

1 (1.5)

16.0

0/1/0/0

Peripheral motor neuropathy

1 (1.5)

3.0

0/0/1/0

Pneumonitis

1 (1.5)

32.0

0/1/0/0

QTc interval prolonged

1 (1.5)

42.0

1/0/0/0

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, DM diabetes mellitus, irAEs immune-related adverse events, QTc corrected QT